Serum uric acid and risk for cardiovascular disease and death: The Framingham heart study

Annals of Internal Medicine

Volumn 131, Issue 1, 1999, Pages 7-13

  Culleton, Bruce F ^a,b   Larson, Martin G ^a   Kannel, William B ^a,c   Levy, Daniel ^a  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERURICEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

EID: 0033529386     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-1-199907060-00003     Document Type: Article

References (57)

1. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med. 1951;34:1421-31.
2. Brand FN, McGee DL, Kannel WB, Stokes J 3d, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol. 1985;121:11-8.
3. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric add to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-Up Study. Am J Epidemiol. 1995;141:637-44.
4. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol. 1989;42:257-67.
5. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand. 1988;224:549-55.
6. Yano K, Reed DM, McGee DL. Ten-year incidence of coronary heart disease in the Honolulu Heart Program. Relationship to biologic and lifestyle characteristics. Am J Epidemiol. 1984;119:653-66.
7. Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl. 1982;668:49-59.
8. Mortality findings for stepped-care and referred-care participants in the Hypertension Detection and Follow-up Program, stratified by other risk factors. The Hypertension and Follow-up Program Cooperative Research Group. Prev Med. 1985;14:312-35.
9. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998;29:635-9.
10. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart. 1997;78:147-53.
11. Liese AD, Hense HW, Lowel H, Doring A, Keil U. Association of serum uric acid with incident myocardial infarction, all cause and CVD mortality in the MONICA Augsburg cohort (Abstract). Circulation. 1998;97:822.
12. Alderman MH, Kivlighn S, Beauchard L, Cohen H, Madhavan S. Increased serum uric acid associated with increased cardiovascular disease in treated hypertensive patients [Abstract]. J Hypertens. 1998;16:5.
13. Alderman MH, Cohen H, Kivlighn S, Madhavan S. Does treatment-mediated increase in uric acid reduce the cardioprotective effect of diuretics in hypertensive patients? [Abstract] Am J Hypertens. 1998;11:16.
14. Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet. 1998;352:670-1.
15. Emmerson BT. Atherosclerosis and urate metabolism. Aust N Z J Med. 1979;9:451-4.
16. Newland H. Hyperuricemia in coronary, cerebral and peripheral arterial disease: an explanation. Med Hypotheses. 1975;1:152-5.
17. Ginsberg MH, Kozin F, O'Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. J Clin Invest. 1977;60:999-1007.
18. Vasquez-Vivar J, Santos AM, Junqueira VB, Augusto O. Peroxynitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals. Biochem J. 1996;314:869-76.
19. Anker SD, Leyva F, Poole-Wilson PA, Kox WJ, Stevenson JC, Coats AJ. Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart. 1997;78:39-43.
20. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18:858-65.
21. Persky VW, Dyer AR, Idris-Soven E, Stamler J, Shekelle RB, Schoenberger JA, et al. Uric acid: a risk factor for coronary heart disease? Circulation. 1979;59:969-77.
22. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol. 1979;110:281-90.
23. Dawber TR, Meadors GF, Moore FE. Epidemiologic approaches to heart disease: the Framingham Heart Study. Am J Public Health. 1951;41:279-86.
24. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-46.
25. Crowley LV. Determination of uric acid. An automated analysis based on a carbonate method. Clin Chem. 1964;10:838-44.
26. Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem. 1952;195:357-66.
27. Shurtleff D. Some characteristics related to the incidence of cardiovascular disease and death: Framingham Heart Study 18-year follow-up. In: Kannel WB, Gordon T, eds. The Framingham Study, Section 30. Washington, DC: U.S. Government Printing Office; 1974:17-25.
28. Cox DR. Regression models and life tables (with discussion). Journal of the Royal Statistical Society. 1972;34:187-220.
29. SAS/STAT Software: Changes and Enhancements through Release 6.11. Cary, NC: SAS Institute; 1996.
30. Wilson PW, Cupples LA, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J. 1991;121:586-90.
31. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes meilitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo study. JAMA. 1991;265:627-31.
32. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med. 1998;158:617-21.
33. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes. 1987;36:523-34.
34. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med. 1973;132:401-10.
35. Stetten DW Jr, Hearton JZ. Intellectual level measured by Army classification battery and serum uric acid concentration. Science. 1959;129:1737-9.
36. Keil U, Stieber J, Doring A, Chambless L, Hartel U, Filipiak B, et al. The cardiovascular risk profile in the study area Augsburg. Results from the first MONICA survey 1984/85. Acta Med Scand Suppl. 1988;728:119-28.
37. Lewis PJ, Kohner EM, Petrie A, Dollery CT. Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet. 1976;1:564-6.
38. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet. 1981;2:539-43.
39. Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT. Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up. Lancet. 1982;2:1293-5.
40. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol. 1998;8:250-61.
41. Reaven GM. Syndrome X: 6 years later. J Intern Med Suppl. 1994;736:13-22.
42. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980;93:817-21.
43. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268:E1-5.
44. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest. 1975;55:845-55.
45. Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA. 1993;270:354-9.
46. Zweier JL, Kuppusamy P, Lutty GA. Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in postischemic tissues. Proc Natl Acad Sci USA. 1988;85:4046-50.
47. Ashraf M, Samra ZQ. Subcellular distribution of xanthine oxidase during cardiac ischemia and reperfusion: an immunocytochemical study. J Submicrosc Cytol Pathol. 1993;25:193-201.
48. Montor SG, Thoolen MJ, Mackin WM, Timmermans PB. Effect of azapropazone and allopurinol on myocardial infarct size in rats. Eur J Pharmacol. 1987;140:203-7.
49. Bolli R. Oxygen-derived free radicals and postischemic myocardial dysfunction ('stunned myocardium'). J Am Coll Cardiol. 1988;12:239-49.
50. Friedl HP, Smith DJ, Till GO, Thomson PD, Louis DS, Ward PA. Ischemia-reperfusion in humans. Appearance of xanthine oxidase activity. Am J Pathol. 1990;136:491-5.
51. Huizer T, de Jong JW, Nelson JA, Czarnecki W, Serruys PW, Bonnier JJ, et al. Urate production by human heart. J Mol Cell Cardiol. 1989;21:691-5.
52. Lazzarino G, Raatikainen P, Nuutinen M, Nissinen J, Tavazzi B, Di Pierro D, et al. Myocardial release of malondialdehyde and purine compounds during coronary bypass surgery. Circulation. 1994;90:291-7.
53. Sahebjani H. Changes in urinary uric acid excretion in obstructive sleep apnea before and after therapy with nasal continuous positive airway pressure. Chest. 1998;113:1604-8.
54. Hayabuchi Y, Matsuoka S, Akita H, Kuroda Y. Hyperuricaemia in cyanotic congenital heart disease. Eur J Pediatr. 1993;152:873-6.
55. Porter KB, O'Brien WF, Benoit R. Comparison of cord purine metabolites to maternal and neonatal variables of hypoxia. Obstet Gynecol. 1992;79:394-7.
56. Saugstad OD. Hypoxanthine as a measurement of hypoxia. Pediatr Res. 1975;9:158-61.
57. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.